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Pulmonary Arterial Hypertension in
Connective Tissue Diseases
Shunji Yoshida1
ABSTRACT
Pulmonary hypertension (PH) was found to be the primary cause of death in mixed connective tissue disease
(MCTD). This led to investigation of the prevalence of PH in other connective tissue diseases (CTD). In 1998,
the Ministry of Health and Welfare’s MCTD Research Committee revealed complication of PH diagnosed by
physicians in 5.02% MCTD patients, 0.90% systemic lupus erythematosus patients, 2.64% systemic sclerosis
patients, and 0.56% polymyositisdermatomyositis patients. These results have been supported by a similar
survey performed in North America.
As quite a few rheumatologists find right heart catheterization difficult to perform, doppler echocardiography
is frequently used for screening and diagnosing PH. The MCTD Research Committee set the revised criteria for
MCTD-PH, in which the threshold of estimated pulmonary arterial systolic pressure value for diagnosis of pul-
monary arterial hypertension (PAH) is set at 36 mmHg, as proposed by the European Society of Cardiology.
Right heart catheterization is strongly recommended for commencing the treatment. Since PH due to throm-
boembolism can potentially be cured surgically, lung perfusion scintigraphy should be performed for all patients
diagnosed with PH.
Most CTD-PH are PAH, and since idiopathic PAH (IPAH) patients sometimes have immune disorders, treat-
ment for IPAH may be applicable to CTD-PH. The greatest difference between the treatment strategy for CTD-
PH and IPAH is the usage of corticosteroids and other immunosuppressants. The MCTD Research Committee
updated its therapeutic guidelines for MCTD-PH in 2011. Validation of these guidelines is also needed.
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CONNECTIVE TISSUE DISEASES (CTD)
AND PULMONARY HYPERTENSION (PH)
CONCEPT OF CTD
CTD cause interstitial fibrinoid degeneration, and are
defined as systemic, non-degenerative, non-neopla-
stic, non-infectious inflammatory diseases. This dis-
ease concept was proposed by Klemperer, a patholo-
gist. He listed six diseases as falling within this con-
cept: systemic lupus erythematosus (SLE); systemic
sclerosis (SSc); polymyositis (PM)dermatomyositis
(DM); rheumatoid arthritis (RA); polyarteritis nodosa
(PN); and rheumatic fever (RF). Other diseases have
since also been considered to fall within this concept.
The six diseases initially proposed by Klemperer are
referred to as classic ‘collagen diseases’, while later
diseases are referred to as diseases related to colla-
gen diseases. Mixed connective tissue disease
(MCTD), one of the diseases related to collagen dis-
eases, was proposed as an independent disease clas-
sification that show mixed characteristics of two or
more of SLE, SSc and PMDM, are positive for anti-
U1-RNP antibodies and show good response to treat-
ment and good prognosis. Collagen diseases are now
called as CTD or collagen vascular diseases.
RELATIONSHIP BETWEEN CTD AND PH
Analysis of the cause of death in MCTD has drawn at-
tention to the involvement of PH in CTD. That is, PH
was found to be the primary cause of death in MCTD,
which had been thought to display good prognosis.
This led to investigation of the prevalence of PH in
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other CTD.
In 1998, the Ministry of Health and Welfare’s
MCTD Research Committee carried out the world’s
first national epidemiological survey.1 Complications
of PH were seen in 83 of 1,651 (5.02%) MCTD pa-
tients, 82 of 9,015 (0.90%) SLE patients, 100 of 3,778
(2.64%) SSc patients, and 19 of 3,349 (0.56%) PMDM
patients. These prevalence can be considered very
high, since the prevalence of idiopathic pulmonary ar-
terial hypertension (IPAH) in the general population
is 1-5 per million. Patients were diagnosed with PH
by physicians because they had shown clinical symp-
toms. On the consideration that other patients with la-
tent PH exhibiting no clinical signs were probably
present, a separate Research Committee of Ministry
of Health, Labour and Welfare in 2003 investigated
PH in CTD patients who were randomly selected, re-
gardless of the presenceabsence of symptoms.2 PH
was detected in 16.0% of MCTD, 9.3% of SLE and
11.4% of SSc patients, and patients with asymptomatic
PH were at least as numerous as those with clinical
signs of PH. This suggests that a similar investigation
is needed in patients with CTD who present with no
signs raising suspicion of PH. The above results gen-
erated in Japan have been supported by a similar sur-
vey performed at 50 institutions in North America.3
That is, PH was diagnosed by the primary physician
and by echocardiography, showing rates of 11.7% and
19.1% in MCTD patients and 18.9% and 27.7% in SSc
patients, respectively. A World Health Organization
(WHO) symposium on PH recommended annual
echocardiography screening for patients with SSc-
related diseases (i.e., SSc and MCTD), regardless of
whether symptoms or changes in symptoms had
been noted.
PATHOPHYSIOLOGY, DISEASE-TYPE CLASSI-
FICATION AND SEVERITY CLASSIFICATION OF
PH ASSOCIATED WITH CTD (CTD-PH)
The causes of pulmonary artery pressure elevation in-
clude causes before and after the pulmonary capillar-
ies. Cases caused before are called precapillary PH,
while cases caused after are called postcapillary PH.
Precapillary PH is also referred to as pulmonary arte-
rial hypertension (PAH). The most recent PH classifi-
cation system is the Dana Point classification,4 de-
scribed in 2008. This system classifies CTD-PH into
the PAH category. However, cases of PH other than
PAH are also seen in CTD patients, and at present
the following four classifications exist on the basis of
the pathogenesis:
・PAH: Caused by stenosis andor occlusion of the
lumen of the peripheral pulmonary artery; the main
pathogenesis of CTD-PH.
・PH due to interstitial pulmonary lesions: Caused
by the load on the right ventricle due to interstitial
pulmonary lesions. In fact, pulmonary arterial pres-
sure does not seem to rise markedly even when the
interstitial pulmonary lesions are severe.
・PH due to chronic pulmonary thromboem-
bolism: This category is divided, according to the re-
sults of lung perfusion scintigraphy, into two groups:
one is chronic macro-thromboembolism that ob-
structs the artery larger than the segmental pulmo-
nary artery and can be distinguished from IPAH, and
the other chronic micro-thromboembolism that ob-
structs the artery smaller than the muscular pulmo-
nary artery and cannot be distinguished from IPAH.
This is often seen in antiphospholipid antibody syn-
drome, and sometimes accompanies severe PAH.
・PAH due to peripheral pulmonary artery vasculi-
tis: Reported in cases of SLE and Takayasu’s arteritis.
NATURAL HISTORY AND PROGNOSIS OF CTD-
PH
The biggest difference between CTD-PH and IPAH is
that, in cases where other symptoms manifest prior
to PH in CTD patients, the possibility exists that PH
can be observed from the time of onset and its natu-
ral history elucidated. The Ministry of Health, Labour
and Welfare’s MCTD Research Committee is thus ap-
plying periodic prospective echocardiographic obser-
vation of MCTD to analyze the natural history of PH.
Interim results indicate that one-third of PH cases in
MCTD show onset prior to diagnosis of MCTD, and
that onset after diagnosis of MCTD takes place rela-
tively early.5 In half of those post-MCTD cases, PH
showed onset within 1 year following onset of MCTD.
PH does not always worsen following onset, and a
patient group with a relatively good prognosis and a
group with poor prognosis have been defined. Statis-
tical analysis using contingency table methods indi-
cated the following factors as being associated with
poor outcomes: pulmonary fibrosis; impaired pulmo-
nary diffusing capacity; exertional retrosternal pain;
left sternal border systolic murmur; fatigability; and
elevated levels of muscle enzymes.6 Multivariate
analysis found associations for polyarthritis, definitive
diagnosis of PH, elevated levels of muscle enzymes
and SSc-related skin lesions. Prognosis was poor for
patients who met the diagnostic criteria for PMDM.
The reasons for an association between myositis and
poor prognosis are unclear, and further studies are
warranted.
DIAGNOSIS OF CTD-PH
CTD-PH and IPAH do not show fundamental differ-
ences. However, since CTD-PH can potentially be
treated with drugs such as immunosuppressants that
cannot be used for IPAH, the importance of early di-
agnosis is obvious.
Doppler echocardiography and right heart cathe-
terization are the most frequently used diagnostic
tools for PH. As quite a few rheumatologists find
right heart catheterization difficult to perform, the
Ministry of Health, Labour and Welfare’s MCTD Re-
PAH in CTD
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Fig.　1　Diagnostic criteria for PH in MCTD.7 †Echocardiography should be performed on MCTD patients even 
when no clinical or laboratory fi ndings suggest PH. ‡Right atrial pressure is postulated to be 5 mmHg. §In the 
case of recognizing the parameters suggestive of PH, other than increased estimated pulmonary artery systolic 
pressure, such as  increased velocity of pulmonary regurgitation, shortened right ventricular ejection time to the 
pulmonary artery, increased diameter of right ventricle, abnormal morphology and function of the interventricular 
septum, increased right ventricular hypertrophy, and/or dilation of the main pulmonary artery, reassessment 
should be performed within at least 1 year even if the estimated pulmonary artery systolic pressure is ≤36 
mmHg. ¶The course of PH should be carefully monitored in cases where right heart catheterization cannot be 
performed. Even when therapy is not started, echocardiography should be performed after 3 months, and the 
patient should be reassessed. ‖For clinical classifi cation and assessment of the severity of PH, right heart cath-
eterization should be strongly recommended before starting treatment.
ePAP, estimated pulmonary arterial systolic pressure.
Clinical and laboratory findings suggestive of PH
A. Exertional dyspnea
Systolic pulsation on the left sternal border
II p sound accentuated
Chest radiography showing dilation of the main trunk of the pulmonary artery or protrusion of
the left II arch.
ECG showing right cardiomegaly or right ventricular load.
B. Elevated BNP or NT-ProBNP
%VC/%DLco ≥1.4
Hyperuricemia
Screening of asymptomatic cases† Echocardiography
ePAP
≤36 mmHg
ePAP
 37-50 mmHg
ePAP
>50 mmHg
‡ ‡ ‡
Satisfies ≥4 of the items in A Satisfies ≥4 of the items in A
No Yes YesNo
PAH is ruled out
(periodic assessment is necessary)§
PAH suspected PAH‖
Right heart catheterization is recommended¶
search Committee set the revised diagnostic criteria
for PH in MCTD (Fig. 1).7 The criteria was revised
with the following five items as the key principles: 1)
measurement of the pulmonary artery pressure is es-
sential for PAH diagnosis; 2) right heart catheteriza-
tion is not mandatory for PAH diagnosis, but is
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Fig.　2　Updated treatment guidelines for PH accompanying MCTD (2011).13 Letters after drug names represent 
the advisability according to reference 11. Within the same advisability, the names of drugs are presented in al-
phabetical order. Only drugs that have been approved in Japan are shown. In Japan, the indication of bosentan 
is limited to NYHA class III or greater. Parentheses are thus used in the column for NYHA class II.
ETR antagonists, endothelin receptor antagonists (ambrisentan, bosentan); PDE 5 inhibitors, phosphodiesterase 
type 5 inhibitors (sildenafi l, tadalafi l); ePAP, estimated pulmonary arterial systolic pressure.
Combined therapy, among the following:
· Epoprostenol A
· Ambrisentan C
· Bosentan C
· Sildenafil C
· Tadalafil C 
Anticoagulant · Diuretics · Oxygen 
Disease activity of CTD 
· Corticosteroids
· Immunsuppressants 
Early phase of PH or
progressive PH 
Continue 
Effective (yes) 
Ineffective (no) 
NYHA II NYHA III NYHA IV 
· Ambrisentan A
· (Bosentan) A
· Sildenafil A
· Ca antagonist B
· Beraprost  
· Ambrisentan A
· Bosentan A
· Sildenafil A
· Epoprostenol A
· Tadalafil B
· Beraprost C  
Atrial septostomy
Lung transplant
ETR antagonist
Prostanoid PDE5 inhibitors
strongly recommended; 3) actual cut off values
should be established for estimated pulmonary artery
systolic pressure (ePAP) in the echocardiography
that is necessary for PAH diagnosis; 4) clinical find-
ings indicative of PH should also be noted; and 5) the
manual is meant for diagnosis of PAH, not PH. The
threshold ePAP value for diagnosis of PAH is set at
36 mmHg, as proposed by the European Society of
Cardiology.8 This diagnostic criteria may also be ap-
plicable to the diagnosis of PH accompanying other
CTD, and we plan to investigate the validity of this ap-
plication for MCTD.
Since PH due to thromboembolism can potentially
be cured surgically, lung perfusion scintigraphy
should be performed for all patients diagnosed with
PH.
THERAPEUTIC APPROACH
PH due to chronic macro-thromboembolism does not
respond to medical therapy. When surgery is indi-
cated, pulmonary thromboendarterectomy should be
performed. Most other cases of CTD-PH are PAH,
and since IPAH patients sometimes have immune dis-
orders, treatment for IPAH may be applicable to
CTD-PH. The following is a simple summary of the
treatment of this CTD-PAH that resembles IPAH:
・Rapid administration of anticoagulant;
・Administration of an effective pulmonary vasodi-
lator to reduce load on the right heart; and
・The patient should rest and be encouraged to
PAH in CTD
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eliminate factors that exacerbate PH, including smok-
ing, infections, fever, anemia, excessive intake of salt
and water, exposure to cold, and fatigue.
Three mechanisms of action are thought to under-
lie PH,9 and drugs are being developed for each. The
first mechanism is the endothelin pathway, mediated
by endothelin as the most powerful in vivo vasocon-
strictor. Drugs are being developed that target endo-
thelin receptor. The second mechanism is the nitric
oxide (NO) pathway. NO is a vasodilator, and sub-
stances are being developed that inhibit phosphodi-
esterase type 5, an enzyme that metabolizes cyclic
GMP, a second messenger in the NO pathway. The
third mechanism is the prostacyclin pathway. Prosta-
cyclin (also known as prostaglandin I2) is also a vaso-
dilator, and analogs are being developed.
As treatment guidelines for IPAH, the American
College of Chest Physicians published updated
evidence-based clinical practice guidelines for medi-
cal therapy for pulmonary arterial hypertension in
2007.10 In 2008, the WHO released updated guide-
lines for recommended therapeutic drugs at the Dana
Point conference.11 The greatest difference between
the treatment strategy for CTD-PH and IPAH is the
usage of corticosteroids and other immunosuppres-
sants. Although there had been no comprehensive re-
port, a retrospective study of immunosuppressive
therapy in a large number of patients was published
in 2006,12 reconfirming the usefulness of this ap-
proach. The MCTD Research Committee updated its
therapeutic guidelines in 201113 (Fig. 2). Validation of
these guidelines is also needed.
CONCLUSION
The incidence of CTD-PH is high, and factors that in-
fluence prognosis have been identified. Many thera-
peutic agents are available, and this disease is now
treatable. Physicians should always keep in mind the
possibility of CTD-PH, strive to achieve early diagno-
sis, and administer appropriate treatment.
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